Zobrazeno 1 - 10
of 56
pro vyhledávání: '"José Manuel Pérez-García"'
Autor:
Serena Di Cosimo, José Manuel Pérez-García, Meritxell Bellet, Florence Dalenc, Miguel J. Gil Gil, Manuel Ruiz-Borrego, Joaquín Gavilá, Elena Aguirre, Peter Schmid, Frederik Marmé, Joseph Gligorov, Andreas Schneeweiss, Joan Albanell, Pilar Zamora, Duncan Wheatley, Eduardo Martínez de Dueñas, Kepa Amillano, Eileen Shimizu, Miguel Sampayo-Cordero, Javier Cortés, Antonio Llombart-Cussac
Publikováno v:
Breast, Vol 76, Iss , Pp 103761- (2024)
Background: The capsule formulation of CDK4/6 inhibitor palbociclib has reduced solubility at gastric pH > 4.5 and may have decreased activity when used with proton-pump inhibitors (PPI). Herein, we report the effect of PPI on palbociclib capsule act
Externí odkaz:
https://doaj.org/article/d3b96315025744e9a531e42906d8d57a
Autor:
Matilde Sánchez-Conde, Pilar Vizcarra, José Manuel Pérez-García, María Gion, María Pilar Martialay, Javier Taboada, Alberto Alonso-Fernández, Miguel Sampayo-Cordero, Andrea Malfettone, Isabel Tena, Sergio De La Torre, Antonio Llombart-Cussac, Javier Cortés
Publikováno v:
International Journal of Infectious Diseases, Vol 123, Iss , Pp 97-103 (2022)
Objectives: Severe COVID-19 is associated with immune dysregulation and hyperinflammation (lymphocyte exhaustion and elevated interleukin 6. Pembrolizumab (P; immune-activating anti-programmed cell death-1 antibody) plus tocilizumab (TCZ; anti- inter
Externí odkaz:
https://doaj.org/article/03300a66cee940b7bc9b769d46d85504
Autor:
Miguel Sampayo-Cordero, Bernat Miguel-Huguet, Andrea Malfettone, Elena López-Miranda, María Gion, Elena Abad, Daniel Alcalá-López, Jhudit Pérez-Escuredo, José Manuel Pérez-García, Antonio Llombart-Cussac, Javier Cortés
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
De-escalation trials in oncology evaluate therapies that aim to improve the quality of life of patients with low-risk cancer by avoiding overtreatment. Non-inferiority randomized trials are commonly used to investigate de-intensified regimens with si
Externí odkaz:
https://doaj.org/article/4129d5abe3b54a4aa1163a0967a18f28
Autor:
María Gion, José Manuel Pérez-García, Antonio Llombart-Cussac, Miguel Sampayo-Cordero, Javier Cortés, Andrea Malfettone
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Drug approval for early-stage breast cancer (EBC) has been historically granted in the context of registration trials based on adequate outcomes such as disease-free survival and overall survival. Improvements in long-term outcomes have made it more
Externí odkaz:
https://doaj.org/article/8b548ce9bba54c9ca2cb0709f0aef8b1
Autor:
Andrea Malfettone, Serena Di Cosimo, José Manuel Pérez-García, Alicia García, Miguel Sampayo-Cordero, Leonardo Mina, Carolina Herrero, Antonio Llombart-Cussac, Javier Cortés
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-3 (2021)
In the global health emergency caused by the COVID-19, clinical trial management has proven to be critical for the pharmaceutical industry, sponsors, and healthcare professionals. Our experience as a sponsor managing interventional oncology clinical
Externí odkaz:
https://doaj.org/article/33b48eb9a9dd438c9f6dd121fdf66906
Autor:
Miguel Sampayo-Cordero, Bernat Miguel-Huguet, Andrea Malfettone, José Manuel Pérez-García, Antonio Llombart-Cussac, Javier Cortés, Almudena Pardo, Jordi Pérez-López
Publikováno v:
Frontiers in Molecular Biosciences, Vol 8 (2021)
Nonrandomized studies are usually excluded from systematic reviews. This could lead to loss of a considerable amount of information on rare diseases. In this article, we explore the impact of excluding nonrandomized studies on the generalizability of
Externí odkaz:
https://doaj.org/article/9f4d7fc64b8344aa8a9954194506836c
Autor:
Elena López-Miranda, José Manuel Pérez-García, Serena Di Cosimo, Etienne Brain, Maja Ravnik, Santiago Escrivá-de-Romaní, Maria Vidal, Joseph Gligorov, Simona Borštnar, Laura Calabuig, Miguel Sampayo-Cordero, Andrea Malfettone, Antonio Llombart-Cussac, Thomas M. Suter, Javier Cortés
Publikováno v:
Cancers, Vol 12, Iss 12, p 3509 (2020)
The paper assesses the dose-limiting toxicities and the maximum tolerated dose (MTD) of trastuzumab emtansine (T-DM1) combined with non-pegylated liposomal doxorubicin (NPLD) in HER2-positive (HER2+) metastatic breast cancer (MBC). This single-arm, o
Externí odkaz:
https://doaj.org/article/5f8e2c4c829544489ee4fefd323d7799
Autor:
José E. Alés-Martínez, Judith Balmaña, Pedro Sánchez-Rovira, Francisco Javier Salvador Bofill, José Ángel García-Sáenz, Isabel Pimentel, Serafin Morales Murillo, Adela Fernández, Ainhara Lahuerta Martínez, Neus Ferrer, Pilar Zamora, Begoña Bermejo, Tamara Díaz-Redondo, María Helena Lopez-Ceballos, María Galán, Andrea Malfettone, Laura Calabuig, Miguel Sampayo-Cordero, José Manuel Pérez-García, Javier Cortés, Antonio Llombart-Cussac
Publikováno v:
Cancer Research. 83:P4-07
Background: Olaparib (O) is approved for the treatment of HER2[-] patients (pts) with early or metastatic breast cancer and a germline BRCA mutation. Nevertheless, there is no evidence that HER2[+] tumors are resistant to PARPi. Preclinical data supp
Autor:
José Manuel Pérez-García, Marta Vaz Batista, Patricia Cortez, Manuel Ruiz-Borrego, Juan Miguel Cejalvo, Juan de la Haba-Rodriguez, Laia Garrigós, Fabricio Racca, Sonia Servitja, Salvador Blanch, María Gion, Monica Nave, María Fernández-Abad, Alejandro Martinez-Bueno, Antonio Llombart-Cussac, Miguel Sampayo-Cordero, Andrea Malfettone, Javier Cortés, Sofía Braga
Publikováno v:
Neuro-Oncology. 25:157-166
Background Trastuzumab deruxtecan (T-DXd) has shown durable antitumor activity in pretreated patients with HER2-positive advanced breast cancer (ABC), but its efficacy has not yet been evaluated in patients with active brain metastases (BMs). DEBBRAH
Autor:
Antonio Llombart-Cussac, Javier Cortés, Andrea Malfettone, Crina Popa, Miguel Sampayo-Cordero, Silvia Menéndez, Federico Rojo, Beatriz Bellosillo, Leonardo Mina, Ana Santaballa Bertran, Vanesa Quiroga, Alessandro Marco Minisini, Enrique Espinosa, Juan de la Haba, Lourdes Calvo, Begoña Bermejo, Meritxell Bellet, Joan Gibert, Laura Comerma, Manuel Ruíz-Borrego, Giuseppe Curigliano, Miguel Gil-Gil, José Manuel Pérez-García, Joan Albanell
Summary of all adverse events according to NCI-CTCAE version 4.0.3.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72568bda800ffb38bd5bdf1659e5cc64
https://doi.org/10.1158/1078-0432.22489440
https://doi.org/10.1158/1078-0432.22489440